Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.
|Title||Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK|
|Date Published||2013 Sep 1|
|Keywords||Adult, Aged, Analgesics, Anti-Anxiety Agents, Antidepressive Agents, Anxiety, Depression, Female, Humans, Hypnotics and Sedatives, Longitudinal Studies, Middle Aged, Neoplasm Grading, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Prospective Studies, Quality of Life, Sleep Wake Disorders, Stress, Psychological, United States|
BACKGROUND: Sleep disturbance is a common clinical complaint of oncology patients and contributes to substantial morbidity. However, because most sleep studies have been cross-sectional, associations between sleep quality and distress in patients with ovarian cancer over time remain unclear. This prospective longitudinal study examined rates of sleep disturbance; contributions of depression, anxiety, and medication use in sleep disturbance; and associations between sleep quality and quality of life (QOL) during the first year after diagnosis among women with ovarian cancer.
METHODS: Women with a pelvic mass completed measures of sleep quality, depression, anxiety, and QOL before surgery. Those diagnosed with primary epithelial ovarian, fallopian tube, or peritoneal cancer repeated surveys at 6 months and 1 year after diagnosis. Mixed modeling was used to examine trajectories of psychosocial measures over time, as well as associations between changes in distress and sleep quality. Relationships between changes in sleep and QOL were also examined.
RESULTS: The majority of patients reported disturbed global sleep (Pittsburgh Sleep Quality Index > 5) at all 3 time points. Medications for sleep and pain were associated with worse sleep at all time points. Greater increases in depression were associated with increased disturbances in sleep quality over time (P < .04). Worsening sleep was also associated with declines in QOL over time (P < .001).
CONCLUSIONS: Sleep disturbance is common and persistent in women with ovarian cancer, and is linked to depressive symptoms and QOL. Pharmacologic treatment does not appear to adequately address this problem. Results highlight the need for ongoing screening and intervention for sleep disturbance in this population.
|PubMed Central ID||PMC3775963|
|Grant List||CA104825 / CA / NCI NIH HHS / United States |
CA140933 / CA / NCI NIH HHS / United States
CA88293 / CA / NCI NIH HHS / United States
R01 CA104825 / CA / NCI NIH HHS / United States
R01 CA140933 / CA / NCI NIH HHS / United States
R21 CA088293 / CA / NCI NIH HHS / United States